On January 22, 2024, Panbela Therapeutics, Inc. received a notice from Nasdaq's Listing Qualifications Department regarding non-compliance with the Minimum Float Requirement following a 1-for-20 reverse stock split on January 18, 2024. The company's common stock is at risk of being delisted from the Nasdaq Capital Market, pending a hearing where Panbela will present its compliance plan. The hearing will address the Minimum Bid Price and Minimum Stockholders’ Equity Requirements, with any delisting action on hold until a decision is made. Panbela's common stock will remain listed until the panel's decision. The company is actively seeking ways to regain compliance with Nasdaq's listing rules. Additionally, Panbela announced that its ASPIRE global clinical trial for the treatment of metastatic pancreatic cancer has surpassed 50% enrollment, with full enrollment expected by Q1 2025 and interim data anticipated by mid-2024. The trial is being conducted across approximately 90 sites worldwide.

On January 22, 2024, Panbela Therapeutics, Inc. received a notice from Nasdaq's Listing Qualifications Department regarding non-compliance with the Minimum Float Requirement following a 1-for-20 reverse stock split on January 18, 2024. The company's common stock is at risk of being delisted from the Nasdaq Capital Market, pending a hearing where Panbela will present its compliance plan. The hearing will address the Minimum Bid Price and Minimum Stockholders’ Equity Requirements, with any delisting action on hold until a decision is made. Panbela's common stock will remain listed until the panel's decision. The company is actively seeking ways to regain compliance with Nasdaq's listing rules. Additionally, Panbela announced that its ASPIRE global clinical trial for the treatment of metastatic pancreatic cancer has surpassed 50% enrollment, with full enrollment expected by Q1 2025 and interim data anticipated by mid-2024. The trial is being conducted across approximately 90 sites worldwide.